| abstract |
In metabolic bone diseases such as osteoporosis, bone strength decreases due to a decrease in bone mass, and pain such as low back pain and fractures occur frequently. Therefore, there is a strong demand for the creation of a drug that can control the overall bone metabolism and increase the bone mass and bone strength. The pharmaceutical composition or combination comprising the non-biologically derived non-peptide osteoblast differentiation promoting compound of the present invention and a bisphosphonate having a bone resorption inhibitory action increases bone mass and / or bone strength by controlling bone metabolism It is useful as an agent for inducing bone mass increase. |